Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
R646227-1mg
|
1mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$151.90
|
|
|
R646227-5mg
|
5mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$318.90
|
|
|
R646227-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$544.90
|
|
|
R646227-50mg
|
50mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$1,508.90
|
|
|
R646227-100mg
|
100mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$2,346.90
|
|
| Specifications & Purity | ≥99% |
|---|---|
| Biochemical and Physiological Mechanisms | 6RK73 is a covalent irreversible and specific UCHL1 inhibitor with an IC 50 of 0.23 µM. 6RK73 shows almost no inhibition of UCHL3 (IC 50 =236 µM). 6RK73 specifically inhibit UCHL1 activity in breast cancer. |
| Storage Temp | Store at -20°C |
| Shipped In |
Ice chest + Ice pads This product requires cold chain shipping. Ground and other economy services are not available. |
| Product Description |
6RK73 is a covalent irreversible and specific UCHL1 inhibitor with an IC 50 of 0.23 µM. 6RK73 shows almost no inhibition of UCHL3 (IC 50 =236 µM). 6RK73 specifically inhibit UCHL1 activity in breast cancer In Vitro 6RK73 (5 μM; 1-3 hours) treatment displays strong inhibition of the TGFβ-induced pSMAD2 and pSMAD3, and a decrease of TβRI and total SMAD protein levels in MDA-MB-436 cells. ?\n6RK73(5 μM; 24-48 hours) results migration significantly slower than the DMSO control group in MDA-MB-436 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: MDA-MB-436 cells Concentration: 5 µM Incubation Time: 24, 48 hours Result: Migrated significantly slower than the DMSO control group Western Blot AnalysisCell Line: MDA-MB-436 cells Concentration: 5 µM Incubation Time: 1, 2, 3 hours Result: Displayed strong inhibition of the TGFβ-induced pSMAD2 and pSMAD3, and a decrease of TβRI and total SMAD protein levels. In Vivo 6RK73 displays a potent inhibition of breast cancer extravasation in zebrafish . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:IC50: 0.23 µM (UCHL1), 236 µM (UCHL3) |
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| IUPAC Name | (3S)-1-cyano-N-(5-morpholin-4-yl-1,3-thiazol-2-yl)pyrrolidine-3-carboxamide |
|---|---|
| INCHI | InChI=1S/C13H17N5O2S/c14-9-17-2-1-10(8-17)12(19)16-13-15-7-11(21-13)18-3-5-20-6-4-18/h7,10H,1-6,8H2,(H,15,16,19)/t10-/m0/s1 |
| InChIKey | ONIHSXKWNFYNNS-JTQLQIEISA-N |
| Smiles | C1CN(CC1C(=O)NC2=NC=C(S2)N3CCOCC3)C#N |
| Isomeric SMILES | C1CN(C[C@H]1C(=O)NC2=NC=C(S2)N3CCOCC3)C#N |
| PubChem CID | 121248200 |
| Molecular Weight | 307.37 |
| Solubility | DMSO : 125 mg/mL (406.68 mM; Need ultrasonic) |
|---|